Saturday 17 October 2026
Export IBRX’s income statement to Excel — free account
ImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024. In the quarter to June 2026, revenue grew 93.9%, EPS fell 120.0%, free cash flow grew 13.4% and total debt rose 57.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
9.18
0.82
−8.20%
Follow IBRX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
28.21 | 16.08 | 55.87 | 55.48 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(33.79) | (25.88) | (104.51) | (138.34) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
36.99 | 22.40 | 61.40 | 60.90 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.55) | (8.32) | (29.40) | (35.92) | |
EV/FCF |
(9.40) | (8.22) | (28.96) | (35.05) | |
Quick Ratio |
5.07 | 4.62 | 6.24 | 5.35 | |
Current Ratio |
5.77 | 5.10 | 6.67 | 5.72 | |
Net Debt/EBITDA |
(4.70) | (3.85) | (4.44) | (7.48) | |
Debt/Assets |
96.50% | 95.06% | 104.91% | 123.21% | |
Debt/Equity |
(0.96) | (0.95) | (0.78) | (0.74) | |
Asset Turnover |
0.19 | 0.26 | 0.30 | 0.32 | |
Operating CF/Net income |
1.02 | 1.14 | 0.12 | 0.29 | |
Capex/Depreciation |
(0.19) | (0.23) | (0.62) | (0.59) | |
Interest Coverage |
(2.02) | (2.30) | (2.67) | (1.97) | |
Research and Development Expense of Revenue |
159.80% | 166.79% | 153.80% | 118.69% | |
Selling, General and Administrative Expense of Revenue |
113.17% | 101.16% | 103.54% | 101.14% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
27.69% | 22.84% | 18.48% | 16.62% | |
Graham Net Nets |
(0.31) | (0.38) | (0.13) | (0.13) | |
Graham Number |
2.23 | 2.15 | 4.02 | 4.66 | |
Earnings Yield |
(16.26%) | (19.19%) | (11.08%) | (11.07%) | |
Free Cash Flow Yield |
(13.95%) | (16.95%) | (3.79%) | (3.13%) | |
Revenue per Share |
0.03 | 0.04 | 0.04 | 0.05 | |
Operating CF per Share |
(0.07) | (0.08) | (0.07) | (0.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.07) | (0.08) | (0.08) | (0.07) | |
Cash per Share |
0.27 | 0.26 | 0.37 | 0.34 | |
Shareholders Equity per Share |
(0.55) | (0.54) | (0.85) | (1.00) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.55) | (0.54) | (0.85) | (1.00) | |
Free Cash Flow |
(69.65) | (71.28) | (77.13) | (70.01) | |
Working Capital |
272.36 | 253.12 | 385.00 | 362.25 | |
Capital Expenditures |
(0.74) | (0.90) | (1.78) | (3.52) | |
Net Current Asset Value |
(712.90) | (686.60) | (1,062.81) | (1,235.28) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.02 | 0.04 | 0.07 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
18.10 | 22.47 | 30.15 | 37.80 | |
Average Payables |
7.86 | 6.85 | 12.35 | 9.71 | |
Average Inventory |
4.33 | 4.59 | 4.50 | 4.29 | |
Average Assets |
441.78 | 442.42 | 475.20 | 515.29 | |
Average Common Equity |
(633.79) | (493.85) | (729.80) | (807.79) |
Columns are period end dates